YairLotanMD

Surgical Oncology

Professor of Urology, Chief of Urologic Oncology Southwestern Medical School; Medical Director of the Urology Clinic at Parkland Health & Hospital System

Join to view full profile

Dr. Lotan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lotan's full profile

Already have an account?

Office
5323 Harry Hines Boulevard
Dallas, TX 75390
Phone+1 214-645-2800

Fax+1 214-645-8772

Education & Training

University of Texas Southwestern Medical CenterResidency, Urology, 1999 - 2003
University of Texas Southwestern Medical CenterResidency, Surgery, 1997 - 1999
Baylor College of MedicineClass of 1997

Certifications & Licensure

TX State Medical License 1999 - 2026
American Board of Urology Urology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2012

Clinical Trials

Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy Start of enrollment: 2014 May 01
Recruiting
Phase 3
Clinical Evaluation of a Test for Monitoring the Recurrence of Bladder Cancer Start of enrollment: 2016 Dec 01
Completed
Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance Start of enrollment: 2019 Mar 11
Recruiting
Phase 3
Gemcitabine Versus Water Irrigation in Upper Tract Urothelial Carcinoma Start of enrollment: 2021 Nov 29
Recruiting
Phase 3
Roles: Contact, Principal Investigator
Measuring Surgical Recovery After Radical Cystectomy Start of enrollment: 2015 Apr 30
Recruiting
Roles: Contact
STRATA: Safe Testing of Risk for AsymptomaTic MicrohematuriA Start of enrollment: 2019 Sep 11
Active, not recruiting
Not Applicable
Roles: Principal Investigator, Contact
STRATA: Safe Testing of Risk for AsymptomaTic MicrohematuriA Start of enrollment: 2019 Sep 11
Active, not recruiting
Not Applicable
Roles: Principal Investigator, Contact
A Novel Multiplex ELISA Assay for Evaluating Patients With Gross Hematuria for Bladder Cancer Start of enrollment: 2016 Dec 30
Recruiting
Roles: Contact
Bladder Cancer Screening Trial Start of enrollment: 2023 May 05
Recruiting
Not Applicable
Roles: Contact, Principal Investigator
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve Start of enrollment: 2021 Apr 22
Recruiting
Phase 1, Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Molecular Subtyping for Predicting Pathological Upstaging and Survival Outcomes in Clinically Organ-confined Bladder Cancer Patients Undergoing Radical Cystectomy.
Joep J de Jong, James A Proudfoot, Siamak Daneshmand, Robert S Svatek, Vikram Narayan
European Urology Open Science. 2025-03-01
Editorial Comment.
Yair Lotan, Solomon Woldu
The Journal of Urology. 2025-03-01
Feasibility and Short-Term Safety of Hydrogel Spacer before Treatment with Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation for Prostate Cancer Trea...
Emily Bochner, Victoria Schulte, Yair Lotan, Xiaosong Meng, Daniel N Costa
Journal of Endourology. 2025-02-10

Journal Articles

Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018
Ashish M Kamat, Yair Lotan, European Urology

Other

Clinical presentation, diagnosis, and staging of bladder cancer
Lotan Y, Choueiri TK
http://www.uptodate.com/contents/clinical-presentation-diagnosis-and-staging-of-bladder-cancer
UpToDate, Wolters Kluwer Health - 2012-08-23

Authored Content

Multi-Institutional Evaluation of the Prognostic Significance of EZH2 Expression in High-Grade Upper Tract Urothelial CarcinomaMay 2018
Multi-Institutional Evaluation of the Prognostic Significance of EZH2 Expression in High-Grade Upper Tract Urothelial CarcinomaMay 2018
Multi-Institutional Evaluation of the Prognostic Significance of EZH2 Expression in High-Grade Upper Tract Urothelial CarcinomaMay 2018
Re: Who Should Be Investigated for Hematuria? Results of a Contemporary Prospective Observational Study of 3556 PatientsApril 2018
Re: Who Should Be Investigated for Hematuria? Results of a Contemporary Prospective Observational Study of 3556 PatientsApril 2018
Join now to see all

Press Mentions

New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer ResearchFebruary 14th, 2025
Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests’ Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU SymposiumFebruary 11th, 2025
New Study Shows Veracyte’s Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder CancerFebruary 5th, 2025
Join now to see all